Gan & Lee Pharmaceuticals Wins Honduras Drug Registration for Vitaglar Insulin Glargine Prefilled PenCoinLive·Jul 9 at 04:07 AM603087+1.22%
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases — Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.MorningStar·Jun 12 at 07:17 AM603087+1.22%
From basic to enhanced, Gan & Lee's GZR4 third item III phase study has met the standards同壁财经·Jun 8 at 09:50 PM603087+1.22%
Gan & Lee Pharmaceuticals' commercialization layout in the Brazilian market has made further progress, achieving dual compliance from raw materials to formulations同壁财经·May 26 at 09:09 AM603087+1.22%
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisationPharmaceutical Technology·Apr 10 at 03:42 AM603087+1.22%
09:36 ETGan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2prnewswire·Mar 31 at 08:37 AM603087+1.22%
Innovative pharmaceutical companies receive intensive research from institutions36Kr·Oct 9, 2025 at 06:31 PM688062+0.46%603087+1.22%
China Galaxy Securities: The future domestic substitution space for diabetes is broad, and innovation is expected to achieve a curve overtakingZhitong·Sep 10, 2025 at 08:23 PM600867+0.36%603087+1.22%
The three major A-share indices rose collectively, with a significant increase in the biopharmaceutical sector. CPO continues to squeeze shorts, while Hong Kong stocks fluctuated and fell, tech stocks retreated, and government bonds and commodities declinedWallstreetcn·Aug 19, 2025 at 03:25 AM002873+2.54%600557+1.42%
The concept of weight loss drugs fluctuates upward, with BOJI CRO and others hitting the limit upZhitong·Aug 18, 2025 at 08:59 PM603087+1.22%300404+2.01%
Gan & Lee: The first subject has been dosed in the Phase II clinical trial of GZR102 injectionZhitong·Aug 8, 2025 at 02:37 AM603087+1.22%
Gan & Lee Pharmaceuticals released its semi-annual performance report, with a net profit attributable to the parent company of 604 million yuan, a year-on-year increase of 101.96%Zhitong·Aug 7, 2025 at 06:04 AM603087+1.22%
